#alecensa

Top Pharma News of the Week – August 20th

All The Most Important Pharmaceutical News Stories Of The Week – August 2018 – Week # 3 Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases

August 14, 2018

Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement to identify new drug candidates for the treatment of pulmonary diseases such as…

Top Pharma News of the Week – May 21st

All The Most Important Pharmaceutical News Stories Of The Week – May 2018 – Week #4 TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

May 15, 2018

TapImmune Inc. has announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. (“Marker”), a privately-held clinical-stage developer of…

U.S. FDA Approves Pfizer’s Bosulif® (Bosutinib) For the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

December 19, 2017

Pfizer Inc. has announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for BOSULIF® (bosutinib) to include adult patients with newly-diagnosed chronic phase…

    Amgen And CytomX Therapeutics Announce Strategic Collaboration in Immuno-Oncology

October 3, 2017

Amgen and CytomX Therapeutics, Inc. have announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target…

Top Pharma News of the Week

FDA Accepts Supplemental Biologics License Application for Prolia® (Denosumab) in Glucocorticoid-Induced Osteoporosis

October 9, 2017

Amgen has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA,…